Literature DB >> 32067992

Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Tova M Bergsten1, Joanna E Burdette2, Matthew Dean3.   

Abstract

Ovarian cancer is the most lethal gynecologic malignancy and the fifth leading cause of cancer-related death in women. Although outcomes have improved in recent years, there remains an unmet clinical need to understand the early pathogenesis of ovarian cancer in order to identify new diagnostic approaches and agents of chemoprevention and chemotherapy. While high grade serous ovarian cancer (HGSOC), the most abundant histotype, was initially thought to arise from the ovarian surface epithelium, there is an increasing body of evidence suggesting that HGSOC originates in the fallopian tube. With this new understanding of cell of origin, understanding of disease development requires analysis with a novel perspective. Currently, factors that drive the initiation and migration of dysplastic tubal epithelial cells from the fallopian tube to the ovary are not yet fully defined. These factors include common mutations to fallopian tube epithelial cells, as well as factors originating from both the fallopian tube and ovary which are capable of inducing transformation and dissemination in said cells. Here, we review these changes, their causative agents, and various potential means of intervention.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; Chemoprevention; Chemotherapy; Oviduct; STIC; TP53

Mesh:

Year:  2020        PMID: 32067992      PMCID: PMC7069002          DOI: 10.1016/j.canlet.2020.02.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  104 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

2.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

3.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination.

Authors:  Lan G Coffman; Daniela Burgos-Ojeda; Rong Wu; Kathleen Cho; Shoumei Bai; Ronald J Buckanovich
Journal:  Transl Res       Date:  2016-03-30       Impact factor: 7.012

Review 4.  Prolactin: structure, function, and regulation of secretion.

Authors:  M E Freeman; B Kanyicska; A Lerant; G Nagy
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

5.  Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.

Authors:  Karthik M Sundaram; Yilin Zhang; Anirban K Mitra; Jean-Louis K Kouadio; Katja Gwin; Anthony A Kossiakoff; Brian B Roman; Ernst Lengyel; Joseph A Piccirilli
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

6.  Haemoglobin in pelvic fluid rescues Fallopian tube epithelial cells from reactive oxygen species stress and apoptosis.

Authors:  Hsuan-Shun Huang; Che-Fang Hsu; Sung-Chao Chu; Pao-Chu Chen; Dah-Ching Ding; Meng-Ya Chang; Tang-Yuan Chu
Journal:  J Pathol       Date:  2016-10-28       Impact factor: 7.996

7.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

8.  Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Authors:  Yu Kang; Archana S Nagaraja; Guillermo N Armaiz-Pena; Piotr L Dorniak; Wei Hu; Rajesha Rupaimoole; Tao Liu; Kshipra M Gharpure; Rebecca A Previs; Jean M Hansen; Cristian Rodriguez-Aguayo; Cristina Ivan; Prahlad Ram; Vasudha Sehgal; Gabriel Lopez-Berestein; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-11-18       Impact factor: 12.531

9.  Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis.

Authors:  Ning Zheng; Jiahang Chen; Weiqun Liu; Jian Liu; Tao Li; Hongning Chen; Jichuang Wang; Lee Jia
Journal:  Oncotarget       Date:  2017-07-17

10.  Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.

Authors:  Laura H Rodgers; Eoghainín Ó hAinmhire; Alexandria N Young; Joanna E Burdette
Journal:  Oncotarget       Date:  2016-05-31
View more
  3 in total

Review 1.  Polyploid giant cancer cells and ovarian cancer: new insights into mitotic regulators and polyploidy†.

Authors:  JoAnne S Richards; Nicholes R Candelaria; Rainer B Lanz
Journal:  Biol Reprod       Date:  2021-08-03       Impact factor: 4.161

Review 2.  Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.

Authors:  Magdalena Cybula; Magdalena Bieniasz
Journal:  Oncotarget       Date:  2022-03-24

Review 3.  Principles of dormancy evident in high-grade serous ovarian cancer.

Authors:  Trevor G Shepherd; Frederick A Dick
Journal:  Cell Div       Date:  2022-03-23       Impact factor: 5.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.